2 results
Approved WMOCompleted
Primary:* To determine the effect of vedolizumab IV compared to adalimumab SC on clinical remission at Week 52.Secondary:* To evaluate the effect of vedolizumab IV compared to adalimumab SC on mucosal healing at Week 52.* To evaluate the effect of…
Approved WMOCompleted
To assess the accuracy of a Bayesian-based, patient-individualized, pharmacodynamic advisory system to optimize propofol effect-compartment-controlled administration using the qCON index as a controlled variable versus qCON-guided effect-compartment…